OverviewSuggest Edit

BerGenBio is an oncology biotech company that develops medicines to treat cancer. The Company develops immuno-oncology drugs, inhibitors, and therapeutics. It also develops clinical trial programmes which focuse on treatment of non-small lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. 

TypePublic
Founded2008
HQBergen, NO
Websitebergenbio.com

Latest Updates

Employees (est.) (Dec 2021)46(-6%)
Share Price (Nov 2021)KR19.6(-1%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at BerGenBio

Stener Kvinnsland

Stener Kvinnsland

Non-Executive Director
Sally Bennett

Sally Bennett

Non-Executive Director
Nigel McCracken

Nigel McCracken

Chief Scientific Officer
Rune Skeie

Rune Skeie

CFO
Debra Barker

Debra Barker

Non-Executive Director
François Thomas

François Thomas

Non-Executive Director
Show more

BerGenBio Office Locations

BerGenBio has offices in Bergen and Oxford
Bergen, NO (HQ)
BBB 91 Jonas Lies vei
Oxford, GB
Magdalen Centre, Robert Robinson Ave
Show all (2)

BerGenBio Financials and Metrics

BerGenBio Revenue

Market capitalization (10-Nov-2021)

1.7b

Closing stock price (10-Nov-2021)

19.6
BerGenBio's current market capitalization is kr1.7 b.
Show all financial metrics

BerGenBio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

BerGenBio Online and Social Media Presence

Embed Graph

BerGenBio News and Updates

Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting

BERGEN, Norway, June 11, 2021 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present updated preliminary survival data from the ongoing Phase II study of...

BerGenBio Receives FDA Fast Track Designation For Bemcentinib / Anti-PD-(L)1 Combination In NSCLC

OSLO, Norway, June 8, 2021 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients

BERGEN, Norway, May 18, 2021 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides top line data from BGBC020, a randomised Phase II clinical study evaluating the...

Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal

DUBLIN, April 14, 2021 /PRNewswire/ -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow,...

BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021)

BERGEN, Norway, Feb. 17, 2021 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for an oral virtual presentation...

BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020

BERGEN, Norway, Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present updated clinical data from two Phase II studies of bemcentinib in acute myeloid...
Show more

BerGenBio Frequently Asked Questions

  • When was BerGenBio founded?

    BerGenBio was founded in 2008.

  • Who are BerGenBio key executives?

    BerGenBio's key executives are Stener Kvinnsland, Sally Bennett and Nigel McCracken.

  • How many employees does BerGenBio have?

    BerGenBio has 46 employees.

  • Who are BerGenBio competitors?

    Competitors of BerGenBio include Luye Pharma, Dragonfly and BrightPath Biotherapeutics.

  • Where is BerGenBio headquarters?

    BerGenBio headquarters is located at BBB 91 Jonas Lies vei, Bergen.

  • Where are BerGenBio offices?

    BerGenBio has offices in Bergen and Oxford.

  • How many offices does BerGenBio have?

    BerGenBio has 2 offices.